AYTU BIOPHARMA, INC Net Income (Loss) Available to Common Stockholders, Diluted
AYTU BIOPHARMA, INC (AYTU) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$5.62 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-05-13
- AYTU BIOPHARMA, INC net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$5.62M, a 424.18% decline year-over-year.
- AYTU BIOPHARMA, INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$10.58M.
- AYTU BIOPHARMA, INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$1.50M.
- AYTU BIOPHARMA, INC net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was $1.73M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2026-03-31 | -$5.62M 10-Q · filed 2026-05-13 | -$16.20M derived: sum of 2 quarters · filed 2026-05-13 | -$14.24M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$10.58M 10-Q · filed 2026-02-03 | -$8.62M 10-Q · filed 2026-02-03 | |
| 2025-09-30 | -$1.50M 10-Q · filed 2025-11-13 | ||
| 2025-03-31 | $1.73M 10-Q · filed 2026-05-13 | -$495.00K derived: sum of 2 quarters · filed 2026-05-13 | -$1.90M 10-Q · filed 2026-05-13 |
| 2024-12-31 | -$2.23M 10-Q · filed 2026-02-03 | -$3.63M 10-Q · filed 2026-02-03 | |
| 2024-09-30 | -$1.41M 10-Q · filed 2025-11-13 | ||
| 2024-03-31 | -$2.89M 10-Q · filed 2025-05-14 | -$3.11M derived: sum of 2 quarters · filed 2025-05-14 | -$11.23M 10-Q · filed 2025-05-14 |
| 2023-12-31 | -$220.00K 10-Q · filed 2025-02-12 | -$8.34M 10-Q · filed 2025-02-12 | |
| 2023-09-30 | -$8.12M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |